Description
The 4 LYSA meeting
Article: The 4 LYSA meeting
€2.42
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: Highlights in melanoma
€2.42 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€147.15 Add to cart
